The Latest Breaking News from Global Blood rapeutics

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

 

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

A Relative Strength Rating upgrade for Global Blood Therapeutic shows improving technical performance.

According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million.

Exclusive: The experiences of more than 1,300 people people living with the illness, carers and healthcare professionals, were examined

According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42 million.

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58 million.